Recover Investment Losses: Class Action Initiated Against Regeneron Pharmaceuticals, Inc. (REGN)
Levi & Korsinsky announced a class action lawsuit against Regeneron Pharmaceuticals on behalf of investors who purchased securities between August 2025 and May 2026. The complaint alleges that Regeneron made misleading statements regarding the Phase III Fianlimab-Libtayo Study, specifically concerning statistical assumptions and clinical differentiation.
Key figures
- Drug Name
- Fianlimab-Libtayo
- Phase Of Trial
- Phase III
- Class period end
- May 15, 2026
- Class period start
- August 1, 2025
- Stock decline may 18
- 9.8%
- Stock decline april 29
- 6.2%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.